Table 1. Baseline characteristics of patients in the ISR group and NISR group.
| Items | ISR group (n=163) | NISR group (n=2,883) | P value |
|---|---|---|---|
| Age (years old) | 59.3±10.2 | 61.7±12.4 | 0.1573 |
| Gender (male, %) | 127 (77.9%) | 2,343 (81.3%) | 0.2872 |
| History, n (%) | |||
| Hyperlipidaemia | 69 (42.3) | 1,147 (39.8) | 0.5184 |
| Hypertension | 77 (47.2) | 1,421 (49.3) | 0.6106 |
| Current smoking | 45 (27.6) | 868 (30.1) | 0.4979 |
| Current alcohol | 62 (38.0) | 1,049 (36.4) | 0.6701 |
| Diabetes | 57 (35.0) | 1,075 (37.3) | 0.5513 |
| PE findings on admission | |||
| BMI (kg/m2) | 27.2±6.7 | 26.5±5.4 | 0.1125 |
| HR (bpm) | 73.8±12.6 | 72.3±14.7 | 0.2019 |
| SBP (mmHg) | 133.6±26.2 | 131.4±30.5 | 0.3670 |
| DBP (mmHg) | 75.2±10.9 | 73.8±9.6 | 0.0723 |
| On admission tests | |||
| Blood glucose (mmol/L) | 6.2±4.1 | 5.1±3.6 | 0.0002 |
| LDL-C (mmol/L) | 2.8±0.9 | 2.3±0.8 | 0.0000 |
| HDL-C (mmol/L) | 0.9±0.4 | 1.0±0.6 | 0.0357 |
| TG (mmol/L) | 2.3±2.1 | 2.1±1.9 | 0.1938 |
| Medication at follow-up, n (%) | |||
| ACEI | 68 (41.7) | 1,254 (48.5) | 0.6558 |
| ARB | 34 (20.9) | 528 (18.3) | 0.4152 |
| BB | 49 (30.1) | 1,043 (36.2) | 0.1132 |
| Statins | 163 (100.0) | 2,883 (100.0) | 1.0000 |
| ASA | 163 (100.0) | 2,883 (100.0) | 1.0000 |
| CLOP | 163 (100.0) | 2,883 (100.0) | 1.0000 |
| CCB | 56 (34.4) | 908 (31.5) | 0.4449 |
| Procedural parameters | |||
| Total stent length (mm) | 37.5±8.6 | 31.6±7.9 | 0.0000 |
| Minimum stents diameters (mm) | 2.7±0.6 | 2.9±0.8 | 0.0017 |
BMI, body mass index; HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride; PE, physical examination; ACEI, angiotensin convert enzyme inhibitor; ARB, angiotensin receptor blocker; BB, β-receptor blocker; ASA, aspirin; CLOP, clopidogrel; CCB, calcium channel blocker.